Compositions and methods of treating cancer
View Patent ↗The present invention provides compositions and methods for treating cancer.
1. A method of treating a tumor in a patient comprising administering to said patient a composition comprising a population of autologous dendritic cell/tumor cell fusions (DC/tumor fusions) and an immunomodulatory agent, wherein the immunomodulatory agent is pomalidomide and/or apremilast.
2. The method of claim 1 , wherein the tumor is a solid tumor.
3. The method of claim 2 , wherein said solid tumor is a breast tumor, or a renal tumor.
4. The method of claim 1 , wherein the tumor is a hematologic malignancy.
5. The method of claim 4 , wherein the hematologic malignancy is acute myeloid leukemia (AML) or multiple myeloma (MM).
6. The method of claim 1 , further comprising administering a checkpoint inhibitor.
7. The method of claim 6 , wherein the checkpoint inhibitor is administered one week after the DC/tumor fusions.
8. The method of claim 6 , wherein the checkpoint inhibitor is a PD1, PDL1, TIM3, or LAG3 antibody.
9. The method of claim 1 , wherein the further comprising administering an agent that targets regulatory T cells.
10. The method of claim 1 , further comprising administering said subject a TLR agonist or tetanus toxoid.
11. The method of claim 10 , wherein the TLR agonist is CPG ODN or polylC.
12. The method of claim 4 , wherein the tumor is multiple myeloma and the patient has received an autologous stem cell transplant 30 to 100 days prior to the administration of the DC/tumor fusions.
13. The method of claim 5 , wherein the tumor is AML and the patient is in post chemotherapy induced remission of AML or with active AML disease.
14. The method in claim 2 , when the composition is administered following surgical resection of tumor for metastatic disease or as adjuvant therapy after removal of the primary tumor.
15. The method of claim 1 , wherein the patient is treated with chemotherapy and the composition is administered 4 to 12 weeks following the completion of the chemotherapy.
16. The method of claim 1 , wherein the composition comprises about 1×10 6 to 1×10 7 DC/tumor fusions.